FDA plans to authorize bivalent boosters by Labor Day, sources say

FDA plans to authorize bivalent boosters by Labor Day, sources say


In this photo illustration, vials and a medical syringe seen in front of the Food and Drug Administration (FDA) of the United States and Pfizer Pharmaceutical company logos. FDA approves Pfizer/BioNTech the COVID-19 coronavirus vaccine for emergency use in the US, reportedly by media.

Pavlo Gonchar | AP

The Food and Drug Administration plans to authorize updated versions of Pfizer-BioNTech’s and Moderna’s Covid boosters around Labor Day, said two people familiar with the discussions.

The Biden administration is preparing to distribute the updated booster shots to teenagers and adults as part of its fall booster campaign.

Both Pfizer’s and Moderna’s so-called bivalent vaccines target the BA.4 and BA.5 omicron subvariants, in addition to the original coronavirus strain in a single shot. BA.5 is responsible for nearly 90% of all new Covid cases in the U.S., according to data from the Centers for Disease Control and Prevention. 

Pfizer is seeking authorization for people 12 and older, while Moderna is seeking authorization for all adults.

The FDA does not plan to convene its advisory panel, the Vaccines and Related Biological Products Advisory Committee, ahead of the authorization, one person said.

The FDA’s authorization will not be the final step before the shots can be distributed. The CDC must also sign off; the agency plans to convene its advisory panel, the Advisory Committee on Immunization Practices, on Sept. 1 and 2 to discuss Covid boosters, according to the agency.

The CDC’s director, Dr. Rochelle Walensky, could sign off on the updated boosters shortly after the two-day meeting. Vaccinations with the updated shots could begin as early as the day after the national holiday, one the people said.

The plan could still change, the people said.

The federal government hopes that by modifying the vaccines to better match circulating strains, it will improve the shots’ effectiveness and perhaps provide longer-lasting immunity.

Both Pfizer’s and Moderna’s applications included data on how well the BA.4/BA.5 booster shot performed in animal studies, but studies in humans have yet to be completed.

The decision to move forward without complete data from human trials has been a sticking point for some outside scientists, who say the new shots have not demonstrated that they are any better than the existing vaccines from Pfizer and Moderna.

Other scientists have praised the unprecedented speed at which Pfizer and Moderna developed the new boosters. BA.5 began spreading throughout the U.S. only in early June.



Source

Trump announces efforts to expand access to IVF drugs
Health

Trump announces efforts to expand access to IVF drugs

U.S. President Donald Trump delivers remarks before signing an executive order on expanding access to IVF at his Mar-a-Lago resort on Feb. 18, 2025 in Palm Beach, Florida. Joe Raedle | Getty Images President Donald Trump on Thursday announced two new efforts to expand the availability of in vitro fertilization, the first concrete step from his […]

Read More
Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers
Health

Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers

A sign is posted in front of a Genentech office on June 12, 2025 in South San Francisco, California. Justin Sullivan | Getty Images Roche‘s Genentech on Thursday said it will sell its flu pill, Xofluza, directly to certain patients at a discount in a bid to expand access, becoming the latest company to wade […]

Read More
DuPont prepares to say goodbye to electronics. What investors get with the remaining company
Health

DuPont prepares to say goodbye to electronics. What investors get with the remaining company

Earlier in the week, we looked at the upcoming DuPont electronics business spinoff and what investors are getting with the new Qnity Electronics, which has a strong foothold in the semiconductor industry. Now, here is a look at what will be left of the new DuPont after the planned Nov. 1 split and the stocks […]

Read More